Nel XVIII secolo, Giovanni Battista Morgagni dimostrò che lesioni localizzate a diversi organi causavano una grande varietà di sintomi e segni clinici. Da allora, la pratica medica si è evoluta notevolmente e mantiene la correlazione dei cambiamenti patologici con i segni e sintomi della malattia nell’ambito dell’attività accademica nota come “seduta anatomico-clinica”. La valutazione dell’attitudine alla correlazione anatomico-clinica non è stata stimata empiricamente in patologia pediatrica.

costruire e validare uno strumento di valutazione per stimare quantitativamente l’attitudine alla correlazione anatomico-clinica nella patologia pediatrica (AA-CCPP). studio analitico trasversale. È stato costruito uno strumento di valutazione con 90 affermazioni vero, falso e non so tipo, raggruppate in base a tre indicatori: I, integrazione diagnostica; II, identificazione di meccanismi patogeni e III, identificazione di dati clinici e paraclinici. Lo strumento è stato applicato a tre gruppi di residenti.

Il test Kruskal-Wallis è stato utilizzato per confrontare i risultati tra i gruppi. il grado AA-CCPP era molto basso nella maggior parte dei residenti. Quando si confrontano i punteggi globali tra i diversi gruppi, il gruppo di patologia pediatrica era il più alto. L’indicatore che ha ottenuto i migliori risultati è stato quello dell’Integrazione Diagnostica. Conclusioni: il livello di sviluppo dell’AA-CCPP osservato ci consente di dedurre che la strategia di apprendimento nota come conferenza clinico-patologica dovrebbe essere rafforzata.

Due chirurghi ortopedici pediatrici sono stati osservati individualmente e le attività sono state programmate durante 3 sessioni cliniche. Uno studente di medicina ha osservato e registrato l’ora utilizzando un foglio di raccolta dati e un orologio. La durata di ogni sessione clinica è stata di 4 ore e un nuovo paziente è stato visitato ogni 20 minuti. I dati sono stati raccolti in 7 categorie tra cui: tempo con il paziente; tempo con il personale; tempo di ascolto delle presentazioni dei residenti, tempo di insegnamento, tempo di multitasking, dettatura del tempo e tempo sulla cartella clinica elettronica (EMR).

Cambiamenti nell’ansia e nella depressione dall’assunzione al primo follow-up tra i giovani transgender in una clinica di endocrinologia pediatrica

 

Il monitoraggio del disagio acuto nei giovani transgender che iniziano cure che affermano il genere è importante dato il loro aumentato rischio di sintomi di salute mentale significativi. L’attuale studio ha esaminato i cambiamenti nell’ansia, nella depressione e nella tendenza al suicidio dall’appuntamento iniziale al primo follow-up in 80 giovani, di età compresa tra 11 e 18 anni. Il tempo medio tra le visite era di ∼4 mesi, ma variava tra i partecipanti.

I risultati non hanno rivelato alcun cambiamento nel disagio acuto dall’assunzione al follow-up. Né la distanza dal centro medico né l’inizio della terapia ormonale sono stati associati a cambiamenti dei sintomi. Mentre la ricerca mostra una diminuzione del disagio con l’inizio degli ormoni, i risultati dello studio suggeriscono che i cambiamenti potrebbero effettivamente richiedere più tempo per verificarsi.

27 pazienti hanno soddisfatto i criteri di inclusione con un’età media di 11,2 anni e una ripartizione razziale dell’85,2% (23) bianco, 11,1% (3) nero e 3,7% (1) multirazziale. Cicatrici cliniche sono state osservate nella maggior parte (23, 85,2%). La biopsia ha confermato la diagnosi nella maggior parte dei casi (24, 88,9%). Le diagnosi più comuni erano follicolite decalvans (6, 22,2%), lichen planopilaris (6, 22,2%), aplasia cutis congenita (4, 14,8%), tinea capitis (4, 14,8%) e morfea (3, 11,1%) . La depressione in comorbidità (6, 22,2%) e l’ansia (6, 22,2%) erano prevalenti.

Tra i pazienti che hanno ricevuto il follow-up, la maggior parte di coloro che hanno seguito il trattamento ha raggiunto la stabilizzazione (55,5%) o il rallentamento della progressione (27,8%), con il 44,4% di quelli trattati che hanno sperimentato la ricrescita. Il tempo medio per la stabilizzazione nella popolazione trattata è stato di 19,6 mesi. Due pazienti non hanno proseguito il trattamento, ma hanno ricevuto un follow-up e questi pazienti non trattati non hanno avuto la ricrescita dei capelli.

Esperienza di iniezioni di tossina botulinica A per l’emicrania cronica in una clinica pediatrica per il dolore cronico

 

La prevalenza dell’emicrania cronica nei bambini può raggiungere il 7,7%, causando una riduzione del rendimento scolastico, difficoltà con attività extracurriculari (inclusi sport, teatro o musica) e cambiamenti nel sonno e nell’umore. Molti studi confermano che le iniezioni di tossina botulinica di tipo A alleviano efficacemente l’emicrania cronica negli adulti; tuttavia, la letteratura sui bambini è scarsa. Questo studio mira ad analizzare la sicurezza e l’efficacia delle iniezioni di botulino di tipo A in un gruppo di pazienti pediatrici con diagnosi di emicrania cronica in una clinica del dolore pediatrico.

in questo studio retrospettivo (2013-2018), gli effetti delle iniezioni di tossina botulinica di tipo A sono stati analizzati utilizzando i dati di 65 pazienti pediatrici con diagnosi di emicrania cronica. Il gruppo di studio variava dagli 11 ai 18 anni di età. Un medico pediatrico per la gestione del dolore ha somministrato il botulino utilizzando il protocollo del programma di terapia di ricerca di fase 3 per la valutazione della profilassi dell’emicrania e ha seguito il modello del dolore. Sono stati misurati i dosaggi, la tolleranza e gli effetti collaterali.

Rabbit Serum, Sterile, Non-hemolized (56-84 days old)
31125-4	Pel-Freez	1L	EUR 355
Description: Produced from whole blood collected from young healthy rabbits (New Zealand White or Californian), 6+ months old. Pooled serum from male and female rabbits that are fasted prior to collection. The serum is processed, bottled, and stored at -20°C. Then the serum was thawed, pooled, passed through a 0.22-micron filter, bottled and returned to -20°C.

Thymus Dissociation System 3 (Epithelial), Rat, less than 6wk old
4-20443	CHI Scientific	ea	Ask for price

Sample diluent buffer
AR1106-1	BosterBio	30ml	EUR 91

RealScreen Pediatric FSH ELISA Kit
EL103-096	GenDepot	96T	EUR 1832

Exo-Urine EV Isolation Kit
EXOU100A-1	SBI	2 x 5 reactions	EUR 551

Urine protein 1
30R-AU008	Fitzgerald	1 mg	EUR 997
Description: Purified native Human Urine protein 1

Pituitary Dissociation System 2 (Pituitary), Rat and mouse less than 2-month-old
4-20402	CHI Scientific	ea	Ask for price

AGEs-BSA
KH001-A	Sceti		EUR 870
Description: The AGEs-BSA is available in Europe and for worldwide shipping via Gentaur.

Epithelial Dissociation System 3 (Epithelial, < 10-day-old rat, Epithelial-like, Esophageal, Uterine), Rat
4-20253	CHI Scientific	ea	Ask for price

pBI121 old Plasmid
PVT3002	Lifescience Market	2 ug	EUR 370

AXYPREP MAG DYECLEAN KIT- 1 ML - (SAMPLE SIZE)
MAG-DYECL-1	CORNING	1/pk	EUR 75
Description: Bioscience Mag Beads; Magnetic Dye

ExoStep Urine
ExoS-25-U9	ImmunoStep	25 test	EUR 550.5

Purified Exosomes from Human Urine (Healthy Donors)
EXOP-520A-1	SBI	>25ug	EUR 477

AXYPREP FRAGMENTSELECT-I KIT- 1 ML - (SAMPLE SIZE)
MAG-FRAG-I-1	CORNING	1/pk	EUR 64
Description: Bioscience Mag Beads; Magnetic Fragment Select

All Sample Diluents Sample Pack
KF17355	Neuromics	3X100 ml	EUR 272

Disposable yellow pipette tips (1-200 ul) for meat sample (1 box 96 tips)
YPT96-1	Alpha Diagnostics	1 pk	EUR 61

AXYPREP MAG PCR NORMALIZER KIT- 1 ML - (SAMPLE SIZE)
MAG-PCR-NM-1	CORNING	1/pk	EUR 73
Description: Bioscience Mag Beads; Magnetic PCR Normaliser

ExoStepTM Urine + Standard
ExoS-25-UST9	ImmunoStep	25 test	EUR 726

IL-4 Interleukin 4 Human Recombinant Protein, Yeast
PROTP05112-4	BosterBio	Regular: 10ug	EUR 317
Description: Interleukin-4 Human Recombinant produced in yeast is a single, glycosylated polypeptide chain containing 129 amino acids.;The IL-4 is purified by proprietary chromatographic techniques.

Sheep AGEs ELISA Kit
ESA0009	Abclonal	96Tests	EUR 521

Mouse AGEs ELISA Kit
EMA0009	Abclonal	96Tests	EUR 521

Anserini AGEs ELISA Kit
EAA0009	Abclonal	96Tests	EUR 521

Rabbit AGEs ELISA Kit
ERTA0009	Abclonal	96Tests	EUR 521

Monkey AGEs ELISA Kit
EMKA0009	Abclonal	96Tests	EUR 521

Porcine AGEs ELISA Kit
EPA0009	Abclonal	96Tests	EUR 521

Rat AGEs ELISA Kit
ERA0009	Abclonal	96Tests	EUR 521

Chicken AGEs ELISA Kit
ECKA0009	Abclonal	96Tests	EUR 521

Goat AGEs ELISA Kit
EGTA0009	Abclonal	96Tests	EUR 521

Bovine AGEs ELISA Kit
EBA0009	Abclonal	96Tests	EUR 521

Sample Diluent
I094	Cygnus Technologies	1000 ml	EUR 519
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

Sample Diluent
I094-100	Cygnus Technologies	100 ml	EUR 211
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

Sample Diluent
I094-500	Cygnus Technologies	500 ml	EUR 373
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

Lung Lysate (0 Days Old)
1402-0	ProSci	0.1 mg	EUR 191
Description: Lung tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Lung Lysate (14 Days Old)
1402-14	ProSci	0.1 mg	EUR 191
Description: Lung tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Lung Lysate (7 Days Old)
1402-7	ProSci	0.1 mg	EUR 191
Description: Lung tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (0 Days Old)
1403-0	ProSci	0.1 mg	EUR 191
Description: Brain tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (14 Days Old)
1403-14	ProSci	0.1 mg	EUR 191
Description: Brain tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (7 Days Old)
1403-7	ProSci	0.1 mg	EUR 191
Description: Brain tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (0 Days Old)
1404-0	ProSci	0.1 mg	EUR 191
Description: Liver tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (14 Days Old)
1404-14	ProSci	0.1 mg	EUR 191
Description: Liver tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (7 Days Old)
1404-7	ProSci	0.1 mg	EUR 191
Description: Liver tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (0 Days Old)
1405-0	ProSci	0.1 mg	EUR 191
Description: Kidney tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (14 Days Old)
1405-14	ProSci	0.1 mg	EUR 191
Description: Kidney tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (7 Days Old)
1405-7	ProSci	0.1 mg	EUR 191
Description: Kidney tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (14 Days Old)
1406-14	ProSci	0.1 mg	EUR 191
Description: Spleen tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (7 Days Old)
1406-7	ProSci	0.1 mg	EUR 191
Description: Spleen tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (14 Days Old)
1409-14	ProSci	0.1 mg	EUR 191
Description: Thymus tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (7 Days Old)
1409-7	ProSci	0.1 mg	EUR 191
Description: Thymus tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (0 Day Old)
1415-0	ProSci	0.1 mg	EUR 191
Description: Stomach tissue lysate (0 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (14 Day Old)
1415-14	ProSci	0.1 mg	EUR 191
Description: Stomach tissue lysate (14 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (7 Day Old)
1415-7	ProSci	0.1 mg	EUR 191
Description: Stomach tissue lysate (7 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (0 Days Old)
1419-0	ProSci	0.1 mg	EUR 191
Description: Skin tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (14 Days Old)
1419-14	ProSci	0.1 mg	EUR 191
Description: Skin tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (7 Days Old)
1419-7	ProSci	0.1 mg	EUR 191
Description: Skin tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (0 Days Old)
1420-0	ProSci	0.1 mg	EUR 191
Description: Eye tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (14 Days Old)
1420-14	ProSci	0.1 mg	EUR 191
Description: Eye tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Eye Lysate (7 Days Old)
1420-7	ProSci	0.1 mg	EUR 191
Description: Eye tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Heart Lysate (14 Days Old)
1401-14	ProSci	0.1 mg	EUR 191
Description: Heart tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Nori® Equine (horse) IL-4 ELISA Kit-Urine
GR106028	Genorise Scientific	96-well	EUR 461

AXYPREP MAG PCR CLEAN UP KIT- 1 ML - (SAMPLE SIZE)
MAG-PCR-CL-1	CORNING	1/pk	EUR 58
Description: Bioscience Mag Beads; Magnetic PCR Clean Up

Individual Reaction Mix 4
G065-4	ABM	200 reactions	EUR 167

Human Cytokine Chemi (4-plex) Sample Demo Kit
MEK2001	BosterBio	Demo kit (Limit 1 kit per lab)	EUR 165

Human Cytokine Chemi (4-plex) Sample Demo Kit
MEK2001-96	BosterBio	Regular 96 Well	EUR 879

Human High Sensitivity (4-plex) Sample Demo Kit
MEK2002	BosterBio	Demo kit (Limit 1 kit per lab)	EUR 165

Human High Sensitivity (4-plex) Sample Demo Kit
MEK2002-96	BosterBio	Regular 96 Well	EUR 879

Mouse Cytokine Chemi (4-plex) Sample Demo Kit
MEK2003	BosterBio	Demo kit (Limit 1 kit per lab)	EUR 165

Mouse Cytokine Chemi (4-plex) Sample Demo Kit
MEK2003-96	BosterBio	Regular 96 Well	EUR 879

CORNING® GOSSELIN™ SAMPLE BLENDER 400ML, 230V
S-BLENDER-1	CORNING	1/pk	EUR 2821
Description: Equipment; Gosselin Equipment

ExoStd? Lyophilized Exosome Standard (30 µg, BPH-1 cell line, 4 vials)
M1062-4	Biovision		EUR 914

ExoStd? Lyophilized Exosome Standard (100 µg, BPH-1 cell line, 4 vials)
M1063-4	Biovision		EUR 1142

Feline IL-4 Recombinant Protein
R00230-4	BosterBio	5ug/vial	EUR 259
Description: IL-4 has many biological roles, including the stimulation of activated B-cell and T-cell proliferation, and the differentiation of CD4+ T-cells into Th2 cells. It is a key regulator in humoral and adaptive immunity. Feline IL-4 Recombinant Protein is purified interleukin-4 produced in yeast.

pLenti-CLDN1 shRNA-4 Plasmid
PVTBAV04867-4	Lifescience Market	2 ug	EUR 356

Human Complete SeraMir Exosome RNA Amplification and Profiling Kit for Media and Urine (contains cat# RA800A-1, RA805A-1, RA810A-1 and EXOTC50A-1 components)
RA820TC-1	SBI	20 profiles	EUR 1618

Mouse Complete SeraMir Exosome RNA Amplification and Profiling Kit for Media and Urine (contains cat# RA800A-1, RA805A-1, RA810A-1 and EXOTC50A-1 components)
RA821TC-1	SBI	20 profiles	EUR 1618

Urine Creatinine Detection Kit
SKT-200-192	Stressmarq	2 plates of 96 wells	EUR 342
Description: Direct Detection kit used for quantitative measuring creatinine in Urine samples from Human, Monkey, Dog, Rat

Fluorescent Exosome Standard (Urine )
ESF-15	Creative Biolabs	100 µg	EUR 1723
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling.

LH (Urine) ELISA Kit
DEIA2231	Creative Diagnostics	96T	EUR 559
Description: The LH (Urine) ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of LH in urine. This test is used to detect the midcycle LH surge in urine, which is an aid in predicting the time of ovulation.

Urine DNA Isolation Kit
K5011150	Biochain	1 kit	EUR 256

ExoPure? Isolation Kit   (Urine)
K1240-10	Biovision		EUR 697

ExoPure? Isolation Kit   (Urine)
K1240-2	Biovision		EUR 403

Cystatin C, Human urine
P1447-100	Biovision		EUR 338

Guinea Pig AGEs ELISA Kit
EGA0009	Abclonal	96Tests	EUR 521

Recombinant Human 4-1BB Receptor Protein
PROTQ07011-4	BosterBio	20ug	EUR 317
Description: 4-1BB Receptor, a member of the TNF superfamily of receptors, is mainly expressed on the surface of a variety of T cells, but also found in B cells, monocytes, and various transformed cell lines. 4-1BB Receptor binds to 4-1BBL to provide a co-stimulatory signal for T lymphocytes. Signaling by 4-1BB Receptor has been implicated in the antigen-presentation process and generation of cytotoxic T cells. The human 4-1BB Receptor gene codes for a 255 amino acid type I transmembrane protein containing a 17 amino acid N-terminal signal sequence, a 169 amino acid extracellular domain, a 27 amino acid transmembrane domain and a 42 amino acid cytoplasmic domain. Recombinant human soluble 4-1BB Receptor is a 167 amino acid polypeptide (17.7 kDa), which contains the cysteine rich TNFR-like extracellular domain of 4-1BB Receptor.

Recombinant Human PF-4 (CXCL4) Protein
PROTP02776-4	BosterBio	20ug	EUR 317
Description: PF-4 is a CXC chemokine that is expressed in megakaryocytes and stored in the α-granules of platelets. PF-4 is chemotactic towards neutrophils and monocytes and has been shown to inhibit angiogenesis. Recombinant human PF-4 is a 7.8 kDa protein containing 70 amino acid residues, including the four highly conserved residues present in CXC chemokines.

Mouse FibrOut 4, for brain, neural
4-20507	CHI Scientific	1 ml	Ask for price

Mouse FibrOut 4, for brain, neural
4-20508	CHI Scientific	5 x 1 ml	Ask for price

Rat FibrOut 4, for brain, neural
4-20533	CHI Scientific	1 ml	Ask for price

Rat FibrOut 4, for brain, neural
4-20534	CHI Scientific	5 x 1 ml	Ask for price

Human FibrOut 4, for brain, neural
4-21552	CHI Scientific	1 ml	Ask for price

Human FibrOut 4, for brain, neural
4-21553	CHI Scientific	5 x 1 ml	Ask for price

DIGITAL SHAKER FOR 4 MICROPLATES, 120V
6780-4	CORNING	1/pk	EUR 798
Description: Lab Equipment; Shakers & Mixers

CORNING® GOSSELIN™ SAMPLE DILUTER 400ML, 220V/110V
S-Diluter-1	CORNING	1/pk	EUR 3955
Description: Equipment; Gosselin Equipment

Heart Lysate (7 day old mouse)
1401-7	ProSci	0.1 mg	EUR 191
Description: Heart tissue lysate (7 day old mouse) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Heart Lysate (0 day old mouse)
1401-0	ProSci	0.1 mg	EUR 191
Description: Heart tissue lysate (0 day old mouse) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Exendin 4 (1-8)
SP-100297-1	Alpha Diagnostics	1 mg	EUR 225

Sample Diluent, 60ML
X028-60ML	Arbor Assays	60ML	EUR 143

BSA Sample Diluent
F031A	Cygnus Technologies	1000 ml	EUR 488
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

BSA Sample Diluent
F031A-100	Cygnus Technologies	100 ml	EUR 195
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

BSA Sample Diluent
F031A-500	Cygnus Technologies	500 ml	EUR 411
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

Sample Denaturing Buffer
F054	Cygnus Technologies	12 ml	EUR 195
Description: Sample Denaturing Buffer by Cygnus Technologies is available in Europe via Gentaur.

Sample Treatment Buffer
F175	Cygnus Technologies	1000 ml	EUR 411
Description: Sample Treatment Buffer by Cygnus Technologies is available in Europe via Gentaur.

Sample Treatment Buffer
F175-100	Cygnus Technologies	100 ml	EUR 219
Description: Sample Treatment Buffer by Cygnus Technologies is available in Europe via Gentaur.

Sample Treatment Plate
F402	Cygnus Technologies	1x 96 wells plate	EUR 103
Description: Sample Treatment Plate by Cygnus Technologies is available in Europe via Gentaur.

Sample Diluent Buffer
I028-100	Cygnus Technologies	100 ml	EUR 211
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur.

Sample Diluent Buffer
I028-1000	Cygnus Technologies	1000 ml	EUR 519
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur.

Sample Diluent Buffer
I028-500	Cygnus Technologies	500 ml	EUR 373
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur.

HEPES Sample Diluent
I050	Cygnus Technologies	1000 ml	EUR 527
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

HEPES Sample Diluent
I050-100	Cygnus Technologies	100 ml	EUR 219
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

HEPES Sample Diluent
I050-500	Cygnus Technologies	500 ml	EUR 334
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

DNA Sample Diluent
D006-100	Cygnus Technologies	100 ml	EUR 373
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

DNA Sample Diluent
D006-1000	Cygnus Technologies	1000 ml	EUR 1167
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

DNA Sample Diluent
D006-500	Cygnus Technologies	500 ml	EUR 726
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur.

Rotavirus Positive Sample
DAG-H10377	Creative Diagnostics	1 ml dry ice	EUR 1105

RSV Positive Sample
DAG-H10378	Creative Diagnostics	1 ml dry ice	EUR 1105

Sample Diluent Buffer
abx296001-20ml	Abbexa	20 ml	EUR 91

ELISA Sample Diluent
ESD125	ScyTek Laboratories	125 ml	EUR 80

ELISA Sample Diluent
ESD500	ScyTek Laboratories	500 ml	EUR 109

ELISA Sample Diluent
ESD999	ScyTek Laboratories	1000 ml	EUR 157

comb 1 mm thick 48 sample
ESEQ1100-C48-1.0	Consort	ea	EUR 99

comb 1 mm thick 80 sample
ESEQ1100-C80-1.0	Consort	ea	EUR 99

comb 1 mm thick 48 sample
ESEQ1200-C24-1.0	Consort	ea	EUR 73

comb 1 mm thick 48 sample
ESEQ1200-C48-1.0	Consort	ea	EUR 73

comb 1 mm thick 10 sample
EVS1100-C10-1.0	Consort	ea	EUR 42

in questo studio, il 74% dei pazienti ha provato più di 6 farmaci prima delle iniezioni. C’è stata una diminuzione nel punteggio della scala analogica visiva di 5,2 ± 2,2 punti dopo 6 settimane di follow-up. La quantità media di farmaco utilizzata è stata di 173,2 ± 35 unità e i pazienti hanno ricevuto una media di 2,8 ± 1,1 unità / kg. Gli eventi avversi includono un paziente che ha sviluppato capogiri e un altro che ha avuto febbri di basso grado con ingrossamento dei linfonodi cervicali; entrambi risolti in pochi minuti.
Conclusioni: questo studio supporta l’uso del tipo botulinico